This is a working overview of melanocortin receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-30 and is reviewed periodically as new material appears.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
== Exocrine cell type == Morphology is what identifies ductal cells. However, there is barely anything to differentiate pancreatic ductal cells from other bodily ductal cells. There is still a lot unknown about these ductal cells. Their molecular identity still needs to be improved; more knowledge is necessary regarding stage-specific markers and the regulators of ductal cell development. It recently was discovered that the ducts start as separate microlumens in a stratified epithelium that expand, attach, and resolve to form the pancreatic ducts. These cells work with intercalating ducts that link to distinct acini and are within the larger ducts in the two core pancreatic ducts (dorsal and ventral duct) that drain into the intestine. Ductal cells are exocrine, but they are more like endocrine cells when developing. A recent lineage analysis showed that ductal cells came directly from bipotent precursor cells and have the possibility of creating either ductal or endocrine cells. Meanwhile, mature ducts have a restricted ability to transdifferentiate to other types of cells, even when the pancreas is injured.
Lemna is a genus of free-floating aquatic plants referred to by the common name "duckweed". They are morphologically divergent members of the arum family Araceae. These rapidly growing plants have found uses as a model system for studies in community ecology, basic plant biology, ecotoxicology, and production of biopharmaceuticals, and as a source of animal feeds for agriculture and aquaculture. Currently, 14 species of Lemna are recognised.
== See also == Abzyme: Antibodies can act as enzymes if they are selected against transition state analogues. Abzymes have a low KM, meaning that they readily bind a target molecule, but have low Vmax values, indicating a slow reaction rate. Biomimetics Bioorthogonal chemistry Catalysis Density functional theory Directed evolution Enzyme Molecular machine Molecularly imprinted polymer Nanochemistry Supramolecular chemistry Zeolite
Sources: en.wikipedia.org
=== Protein === As a GRX family protein, Grx2 has an N-terminal thioredoxin domain, possessing a 37CSYC40 active site motif with a serine residue replacing the conserved proline residue. This amino acid substitution allows the main chain of Grx2 to be more flexible, promoting coordination of the iron-sulfur cluster and facilitating deglutathionylation by enhanced glutathione-binding. The cysteine pair (Cys28, Cys113) falls outside of the active site, and it is completely conserved in Grx2 proteins but not found in some other GRX family proteins (i.e. Grx1 and Grx5). A disulfide bond between this cysteine pair increases structural stability and provides resistance to over-oxidation induced enzymatic inactivation.
== Murders and investigation == In June 2015, Mays began working as a nursing assistant at the Louis A. Johnson Veterans Medical Center in Clarksburg, West Virginia, with no certification or license to care for patients. Nursing assistants at the VAMC are not qualified or authorized to administer any medication to patients, including insulin. Mays was assigned to work overnight shifts on Ward 3A of the hospital's medical surgical unit in July 2017, when elderly patients began suffering mysterious acute drops in their blood sugar level. Over the course of eleven months, hospital staff eventually attributed the deaths of several patients on the ward to hypoglycemia. Many of the deaths were of individuals who were not insulin-dependent. Four of the deaths occurred within sixteen days. One patient, Archie Edgell, an 84-year-old Korean War veteran, initially suffered a drop in his blood sugar to 24 (a reading of less than 70 is low and can be harmful.) He was stabilized by staff, only to die after another plummet of his blood sugar a short time later. An autopsy later found that Edgell had been injected four times. The hospital began an internal investigation of eleven deaths. Mays was fired from the hospital in June 2018, and the investigation was turned over to the Inspector General for the United States Department of Veterans Affairs and the Federal Bureau of Investigation. A total of 112 patients on Ward 3A died while Mays was employed there as a nursing assistant. Of those deaths, 66 experienced one hypoglycemic event.
Later 1987 experiments on the longer-lived isotope 260Lr confirmed lawrencium's trivalency and that it eluted in roughly the same place as erbium, and found that lawrencium's ionic radius was 88.6±0.3 pm, larger than would be expected from simple extrapolation from periodic trends. Later 1988 experiments with more lawrencium atoms refined this to 88.1±0.1 pm and calculated an enthalpy of hydration value of −3685±13 kJ/mol. It was also found that the actinide contraction at the end of the actinides was larger than the analogous lanthanide contraction, with the exception of the last actinide, lawrencium: the cause was speculated to be relativistic effects. It has been speculated that the 7s electrons are relativistically stabilized, so that in reducing conditions, only the 7p1/2 electron would be ionized, leading to the monovalent Lr+ ion. However, all experiments to reduce Lr3+ to Lr2+ or Lr+ in aqueous solution were unsuccessful, similarly to lutetium. On the basis of this, the standard electrode potential of the E°(Lr3+ → Lr+) couple was calculated to be less than −1.56 V, indicating that the existence of Lr+ ions in aqueous solution was unlikely. The upper limit for the E°(Lr3+ → Lr2+) couple was predicted to be −0.44 V: the values for E°(Lr3+ → Lr) and E°(Lr4+ → Lr3+) are predicted to be −2.06 V and +7.9 V. The stability of the group oxidation state in the 6d transition series decreases as RfIV > DbV > SgVI, and lawrencium continues the trend with LrIII being more stable than RfIV.
Sources: en.wikipedia.org
Mass spectrometry is one of the key methods to study the proteome. Some important mass spectrometry methods include Orbitrap Mass Spectrometry, MALDI (Matrix Assisted Laser Desorption/Ionization), and ESI (Electrospray Ionization). Peptide mass fingerprinting identifies a protein by cleaving it into short peptides and then deduces the protein's identity by matching the observed peptide masses against a sequence database. Tandem mass spectrometry, on the other hand, can get sequence information from individual peptides by isolating them, colliding them with a non-reactive gas, and then cataloguing the fragment ions produced. In May 2014, a draft map of the human proteome was published in Nature. This map was generated using high-resolution Fourier-transform mass spectrometry. This study profiled 30 histologically normal human samples resulting in the identification of proteins coded by 17,294 genes. This accounts for around 84% of the total annotated protein-coding genes.
When Sauropsida was used, it often had the same content or even the same definition as Reptilia. In 1988, Jacques Gauthier proposed a cladistic definition of Reptilia as a monophyletic node-based crown group containing turtles, lizards and snakes, crocodilians, and birds, their common ancestor and all its descendants. While Gauthier's definition was close to the modern consensus, nonetheless, it became considered inadequate because the actual relationship of turtles to other reptiles was not yet well understood at this time. Major revisions since have included the reassignment of synapsids as non-reptiles, and classification of turtles as diapsids. Gauthier 1994 and Laurin and Reisz 1995's definition of Sauropsida defined the scope of the group as distinct and broader than that of Reptilia, encompassing Mesosauridae as well as Reptilia sensu stricto. A variety of other definitions were proposed by other scientists in the years following Gauthier's paper. The first such new definition, which attempted to adhere to the standards of the PhyloCode, was published by Modesto and Anderson in 2004. Modesto and Anderson reviewed the many previous definitions and proposed a modified definition, which they intended to retain most traditional content of the group while keeping it stable and monophyletic. They defined Reptilia as all amniotes closer to Lacerta agilis and Crocodylus niloticus than to Homo sapiens.
== Further reading == Collip, James (May 1941). "Frederick Grant Banting, Discoverer of Insulin". The Scientific Monthly. 52 (5): 472–474. Bibcode:1941SciMo..52..472C. JSTOR 17312. Banting, F.G. & Best, C.H. (1922), "The Internal Secretions of the Pancreas", The Journal of Laboratory and Clinical Medicine, Vol.7, No.5, (February 1922), pp. 251–266. Banting, F.G., Best, C.H., Collip, J.B., Campbell, W.R. & Fletcher, A.A. (1922), "Pancreatic Extracts in the Treatment of Diabetes Mellitus", The Canadian Medical Association Journal, Vol.12, No.3, (March 1922), pp.141–146. US patent no.1,469,994 (held by "Frederick G. Banting and Charles Herbert Best, of Toronto, Ontario, and James Bertram Collip of Edmonton, Alberta, Canada"), (filed: 12 January 1923), (patented: 9 October 1923), for "Extract Obtainable from the Mammalian Pancreas or from the Related Glands in Fishes, Useful in the Treatment of Diabetes Mellitus, and a Method of Preparing it". Best, C. H. (November 1, 1942). "Frederick Grant Banting 1891–1941". Obituary Notices of Fellows of the Royal Society. 4 (11): 20–26. doi:10.1098/rsbm.1942.0003. S2CID 162239410. Bliss, Michael (1992) [1984]. Banting: A Biography. Toronto, Ontario: University of Toronto Press. ISBN 978-0-8020-7387-7. Banting, F. G.; Best, C. H. (2009). "The Journal of Laboratory and Clinical Medicine: Vol. VII St. Louis, February, 1922 No. 5". Nutrition Reviews. 45 (4): 55–57. doi:10.1111/j.1753-4887.1987.tb07442.x. PMID 3550540. Bliss, Michael (1990) [1982]. The Discovery of Insulin (3rd ed.). University of Toronto Press. ISBN 978-0-8020-8344-9.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
Mass spectrometry combined with liquid chromatography provides both molecular weight confirmation and a measure of related impurities. Tandem mass spectrometry adds sequence information. A purity percentage reported without a mass measurement does not confirm what the material is.